Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Chair: GlaxoSmithKline Partnered - Operating Component

McGill University

$137,500.00

Better understanding of chronic obstructive pulmonary disease (COPD) and intervention guides

EF 2014-15

Résumé
Chronic obstructive pulmonary disease (COPD) is the 4th cause of mortality and it is projected to move up to the 3rd rank by 2020. Mortality has increased and COPD results in higher rates of hospitalization than heart failure, angina and other chronic diseases. COPD remains under diagnosed and undertreated, and under prioritized by policy and decision makers. We are proposing a new model of research, the Canadian Chronic Obstructive Lung Disease (CanCOLD) project that will position COPD research for strong leadership and partnership (with COPD community, academic institution and industry), and alliance opportunities at National and International levels. CanCOLD as a research project provides unique and exclusive feature including sampling in the population that can better mirror the population of COPD patients at large, longitudinal assessment with repeated measurements (3 years and beyond) and extensive characterization of men and women with early disease. CanCOLD will allow identifying clinical subgroups 'phenotypes' and how factors can affect outcomes in patients, with assessment of other determinants than smoking that might impact on disease progression, and comorbidities. CanCOLD as a network platform gives access to a comprehensive dataset and a centralized tissue bank (blood storage for measuring biomarkers, DNA, RNA). It has led to high profile transdisciplinary collaboration involving researchers from most universities across Canada and collaborative engagement with industry to maximise value to COPD community with several substudies inspired by practical considerations. Through these studies, the industry partner will contribute to enhance academic research output and generate university benefits; in particular, new research findings and knowledge will likely be more rapidly applicable to practice.
Programme
Chair: GlaxoSmithKline Partnered - Operating Component
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
327652
Name
Bourbeau Jean
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
GlaxoSmithKline (Mississauga, Ontario)
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
CIHR/GSK Partnered Chair Program
Projecttitle
Better understanding of chronic obstructive pulmonary disease (COPD) and intervention guides
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$137,500
Cihrequipment2
$0
Programname2
Chair: GlaxoSmithKline Partnered - Operating Component
Keyworddelim
Biomarker; Chronic Disease; Copd; Health Care System; Patient Outcome; Phenotype; Population Health; Risk Factors; Sex And Gender
Abstract
Chronic obstructive pulmonary disease (COPD) is the 4th cause of mortality and it is projected to move up to the 3rd rank by 2020. Mortality has increased and COPD results in higher rates of hospitalization than heart failure, angina and other chronic diseases. COPD remains under diagnosed and undertreated, and under prioritized by policy and decision makers. We are proposing a new model of research, the Canadian Chronic Obstructive Lung Disease (CanCOLD) project that will position COPD research for strong leadership and partnership (with COPD community, academic institution and industry), and alliance opportunities at National and International levels. CanCOLD as a research project provides unique and exclusive feature including sampling in the population that can better mirror the population of COPD patients at large, longitudinal assessment with repeated measurements (3 years and beyond) and extensive characterization of men and women with early disease. CanCOLD will allow identifying clinical subgroups 'phenotypes' and how factors can affect outcomes in patients, with assessment of other determinants than smoking that might impact on disease progression, and comorbidities. CanCOLD as a network platform gives access to a comprehensive dataset and a centralized tissue bank (blood storage for measuring biomarkers, DNA, RNA). It has led to high profile transdisciplinary collaboration involving researchers from most universities across Canada and collaborative engagement with industry to maximise value to COPD community with several substudies inspired by practical considerations. Through these studies, the industry partner will contribute to enhance academic research output and generate university benefits; in particular, new research findings and knowledge will likely be more rapidly applicable to practice.
Competitiondate
201503
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Bourbeau, Jean
Approvedterm
5 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $137,500~ $0~